Partner of choice for novel immunotherapeutics
Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.
If you’re interested in discussing our programmes, please get in touch